China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
This article was originally published in The Gray Sheet
Executive Summary
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.
You may also be interested in...
Mindray Doubles Patient Monitor Biz, Builds U.S. Presence With Acquisition
China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11
New EU Filings
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.
Pipeline Watch: Japan Dominates 25 New Approvals, Plus Six Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.